Harrow Health stock gets TYRVAYA after USD 30 million deal

Published on 10/05/2026 at 19:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Harrow Health stock gets TYRVAYA after a USD 30 million closing payment on October 5, 2026. Q2 revenue reached USD 70.66 million, up 10.9 percent year over year.

HROW, US4158581094, Illustration mit AI erstellt.

Harrow Health stock was trading at USD 30.69 on Nasdaq at 1:56 p.m. ET on October 5, 2026, up 0.69 percent on the session. The company completed its TYRVAYA acquisition for USD 30 million in cash, creating a new commercial leg in dry eye treatment.

TYRVAYA deal adds a growth asset

According to GlobeNewswire on October 5, 2026, Harrow acquired worldwide rights to TYRVAYA except for Japan. The payment structure includes up to USD 70 million in sales-based milestone payments, putting the potential transaction value at USD 100 million.

Harrow expects TYRVAYA to contribute more than USD 30 million in revenue in 2027, while integration begins in the fourth quarter of 2026. The nasal spray is approved for dry eye disease and complements VEVYE, Harrow's existing prescription therapy for the same condition.

Revenue growth meets a loss

The acquisition arrives after a mixed second quarter. MarketBeat reported Q2 2026 revenue of USD 70.66 million versus USD 63.74 million a year earlier, an increase of 10.9 percent. The company reported adjusted? No, the result was a GAAP loss of USD 0.46 per share against a consensus loss of USD 0.18.

The contrast matters for the deal thesis: sales are expanding, but the quarterly earnings shortfall shows that commercial investment and integration costs remain important variables. Harrow's 2026 Q2 revenue was USD 70.661 million in the standardized financial statements, while total assets stood at USD 416.816 million at June 30, 2026.

Analyst target stays above the quote

MarketBeat cited a Moderate Buy consensus based on 11 analysts, with an average price target of USD 69.43. At the Nasdaq price of USD 30.69 on October 5, 2026, that target lies 126.3 percent above the price, although the same consensus also included targets from USD 45.00 to USD 88.00.

That spread points to execution as the central variable. TYRVAYA gives Harrow an established dry eye product, but the company must convert the acquisition into prescriptions while absorbing the commercial expansion tied to the integration.

Harrow Health stock trades at USD 30.69

Harrow Health stock was last at USD 30.69 on Nasdaq at 1:56 p.m. ET on October 5, 2026, with a market capitalization of USD 1.1 billion and volume of 239,916 shares. The 52-week range is USD 28.54 to USD 54.85.